nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
A Cost-effectiveness Analysis of Systemic Therapy for Metastatic Hormone-sensitive Prostate Cancer
|
Sathianathen, Niranjan J. |
|
|
2 |
6 |
p. 649-655 |
artikel |
2 |
Comparison of Magnetic Resonance Imaging-stratified Clinical Pathways and Systematic Transrectal Ultrasound-guided Biopsy Pathway for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials
|
Woo, Sungmin |
|
|
2 |
6 |
p. 605-616 |
artikel |
3 |
Complications and Adverse Events of Three Magnetic Resonance Imaging–based Target Biopsy Techniques in the Diagnosis of Prostate Cancer Among Men with Prior Negative Biopsies: Results from the FUTURE Trial, a Multicentre Randomised Controlled Trial
|
Wegelin, Olivier |
|
|
2 |
6 |
p. 617-624 |
artikel |
4 |
Contents
|
|
|
|
2 |
6 |
p. iii-v |
artikel |
5 |
Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
|
Graham, Jeffrey |
|
|
2 |
6 |
p. 643-648 |
artikel |
6 |
Development and Validation of an Improved Pathological Nodal Staging System for Urothelial Carcinoma of the Bladder
|
Patel, Devin N. |
|
|
2 |
6 |
p. 656-663 |
artikel |
7 |
Editorial Board
|
|
|
|
2 |
6 |
p. i-ii |
artikel |
8 |
First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis
|
Hahn, Andrew W. |
|
|
2 |
6 |
p. 708-715 |
artikel |
9 |
Genomic Risk Predicts Molecular Imaging-detected Metastatic Nodal Disease in Prostate Cancer
|
Xu, Melody J. |
|
|
2 |
6 |
p. 685-690 |
artikel |
10 |
Impact of Hospital Case Volume on Outcomes Following Radical Nephrectomy and Inferior Vena Cava Thrombectomy
|
Freifeld, Yuval |
|
|
2 |
6 |
p. 691-698 |
artikel |
11 |
Long-term Outcomes for Men in a Prostate Screening Trial with an Initial Benign Prostate Biopsy: A Population-based Cohort
|
Palmstedt, Emmeli |
|
|
2 |
6 |
p. 716-722 |
artikel |
12 |
Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy
|
Thang, Sue Ping |
|
|
2 |
6 |
p. 670-676 |
artikel |
13 |
Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial
|
Armstrong, Andrew J. |
|
|
2 |
6 |
p. 677-684 |
artikel |
14 |
Recurrent Ta Low-grade Non-muscle-invasive Bladder Cancer: What Are the Options?
|
Rouprêt, Morgan |
|
|
2 |
6 |
p. 723-729 |
artikel |
15 |
Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study
|
Procopio, Giuseppe |
|
|
2 |
6 |
p. 699-707 |
artikel |
16 |
What Is the Prognostic and Clinical Importance of Urothelial and Nonurothelial Histological Variants of Bladder Cancer in Predicting Oncological Outcomes in Patients with Muscle-invasive and Metastatic Bladder Cancer? A European Association of Urology Muscle Invasive and Metastatic Bladder Cancer Guidelines Panel Systematic Review
|
Veskimäe, Erik |
|
|
2 |
6 |
p. 625-642 |
artikel |
17 |
Who Benefits from Multiparametric Magnetic Resonance Imaging After Suspicion of Prostate Cancer?
|
Morote, Juan |
|
|
2 |
6 |
p. 664-669 |
artikel |